S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
The A.I. story nobody is telling you (Read ASAP) (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
How major US stock indexes fared Friday, 4/19/2024
SHOCKING Crypto Leak… (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
The A.I. story nobody is telling you (Read ASAP) (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
How major US stock indexes fared Friday, 4/19/2024
SHOCKING Crypto Leak… (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
The A.I. story nobody is telling you (Read ASAP) (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
How major US stock indexes fared Friday, 4/19/2024
SHOCKING Crypto Leak… (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
The A.I. story nobody is telling you (Read ASAP) (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
How major US stock indexes fared Friday, 4/19/2024
SHOCKING Crypto Leak… (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Free Trial
NASDAQ:UROV

Urovant Sciences (UROV) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)
Free UROV Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$16.24
▼
$16.24
50-Day Range
$16.19
▼
$16.24
52-Week Range
$7.15
▼
$16.26
Volume
N/A
Average Volume
114,469 shs
Market Capitalization
$531.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
UROV stock logo

About Urovant Sciences Stock (NASDAQ:UROV)

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

UROV Stock News Headlines

March 26, 2024 | finance.yahoo.com
A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors
December 6, 2023 | finance.yahoo.com
Petauri™ Elects William Fleming and James Robinson to Its Board of Directors
April 19, 2024 | Crypto 101 Media (Ad)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
October 4, 2023 | finance.yahoo.com
PM360 Announces 2023 Trailblazer Award Winners
September 11, 2023 | finance.yahoo.com
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
July 31, 2023 | finance.yahoo.com
CNVCF - BioHarvest Sciences Inc.
July 25, 2023 | businesswire.com
UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors
July 20, 2023 | benzinga.com
Benign Prostatic Hyperplasia Therapeutics Market Size Predictions suggest a rise of 5.1% CAGR, to reach value of USD 12.9 Billion by 2032
April 19, 2024 | Crypto 101 Media (Ad)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
June 24, 2023 | npr.org
KPCW Cool Science Radio
June 9, 2023 | uk.finance.yahoo.com
Overactive Bladder Treatment Global Market Report 2023
May 22, 2023 | finanznachrichten.de
Pierre Fabre announces start of EU marketing authorization application procedure for Vibegron in overactive bladder
May 3, 2023 | bizjournals.com
Three Japanese pharma subsidiaries to lay off 223 in Marlborough
March 28, 2023 | finance.yahoo.com
Overactive Bladder Market to Grow Rapidly at a Considerable CAGR During the Forecast Period (2023–2032) | DelveInsight
February 19, 2023 | marketwatch.com
Drugs for Enuresis Market 2023: Growth by 2029 Top Players with Opportunities
January 19, 2023 | technews.tmcnet.com
Urovant Sciences® Announces Collaboration with Holly Robinson Peete to Help Raise Awareness for Overactive Bladder and Treatment Options
January 16, 2023 | marketwatch.com
Drugs for Enuresis Market Share From 2023 To 2029 And Unlimited Opportunities for New Companies and Latest Developments
December 21, 2022 | msn.com
How To Deal With An Overactive Bladder If You're Traveling Long Distance Over The Holidays
December 20, 2022 | seekingalpha.com
Roivant Sciences: A Solid Year Of Progress And Good Prospects For 2023
October 27, 2022 | finance.yahoo.com
Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet
October 4, 2022 | seekingalpha.com
Myovant: Sumitomo Bid Is A Head Scratcher, Where Is The Value?
September 30, 2022 | financialpost.com
'I lose money every time I leave the house': Inflation complicates back-to-office push
September 26, 2022 | investopedia.com
Social Science: What It Is and the 5 Major Branches
September 13, 2022 | usnews.com
Best Global Universities for Computer Science
September 10, 2022 | npr.org
Science Friday
September 8, 2022 | cnbc.com
Health and Science
September 7, 2022 | finanznachrichten.de
Urovant Sciences, Inc.: Urovant Sciences Named 17th on the List of Fortune Best Workplaces in BioPharma (2022)
See More Headlines
Receive UROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Urovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/11/2021
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:UROV
CUSIP
N/A
CIK
1740547
Web
www.urovant.com
Phone
44-0-20-7400-3347
Fax
N/A
Employees
70
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($4.71)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-146,740,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-162.90%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.91
Quick Ratio
2.91

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.90) per share
Price / Book
-8.55

Miscellaneous

Outstanding Shares
32,743,000
Free Float
N/A
Market Cap
$531.75 million
Optionable
Not Optionable
Beta
2.36
The Best High-Yield Dividend Stocks for 2024 Cover
The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. James A. Robinson Jr. (Age 50)
    Pres, CEO & Director
    Comp: $1.07M
  • Mr. Ajay Bansal (Age 59)
    CFO & Sr. VP of Bus. Devel.
    Comp: $558.34k
  • Dr. Cornelia Haag-Molkenteller M.D. (Age 62)
    Ph.D., Chief Medical Officer of USI
    Comp: $629.79k
  • Ms. Christine G. Ocampo (Age 49)
    Chief Accounting Officer & Sr. VP
  • Ryan Kubota
    Exec. Director of Investor Relations
  • Mr. Bryan E. Smith (Age 42)
    Gen. Counsel
  • Dr. David Hovland
    Sr. VP of Global Regulatory Affairs
  • Mr. Kenton Stewart
    Sr. VP of Market Access

Key Competitors

View All Competitors

UROV Stock Analysis - Frequently Asked Questions

How were Urovant Sciences' earnings last quarter?

Urovant Sciences Ltd. (NASDAQ:UROV) announced its quarterly earnings results on Thursday, February, 11th. The company reported ($1.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.59) by $0.13.

What other stocks do shareholders of Urovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Urovant Sciences investors own include Fulcrum Therapeutics (FULC), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), AVEO Pharmaceuticals (AVEO), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Provention Bio (PRVB), SCYNEXIS (SCYX) and Xeris Biopharma (XERS).

When did Urovant Sciences IPO?

Urovant Sciences (UROV) raised $150 million in an initial public offering on Thursday, September 27th 2018. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO.

This page (NASDAQ:UROV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
SHOCKING Crypto Leak…
Crypto 101 Media
The #1 Crypto for 2024
InvestorPlace
How Biden has already won 2024
Porter & Company
Urgent alert: open this for a huge profit potential
Timothy Sykes